ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Bayer Announces KERENDIA® (finerenone) Reduces the Risk of Cardiovascular Outcomes in New Phase III FIGARO-DKD Study in Adults With Chronic Kidney Disease (Stages 1-4) Associated With Type 2 Diabetes

August 28, 2021 GMT

WHIPPANY, N.J.--(BUSINESS WIRE)--Aug 28, 2021--

Bayer announced today that detailed results from the Phase III FIGARO-DKD study demonstrated that compared with placebo, KERENDIA ® (finerenone) – a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) 3,4 – significantly reduced the risk of the composite primary endpoint of time to first occurrence of cardiovascular (CV) death or nonfatal CV events (myocardial infarction, stroke or heart failure hospitalization) by 13% (relative risk reduction, HR 0.87 [95% CI, 0.76-0.98; P =0.0264]) over a median duration of follow-up of 3.4 years when added to maximum tolerated labeled dose of angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) in adults with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). 1 The reduction in the CV composite outcome was primarily driven by hospitalization due to heart failure. These data were presented today during a Hot Line session at the ESC Congress 2021 and simultaneously published in the New England Journal of Medicine.

ADVERTISEMENT

FIGARO-DKD is the first contemporary Phase III cardiorenal trial with the majority of patients with stages 1-2 CKD (estimated glomerular filtration rate [eGFR] ≥60 ml/min/1.73m 2 ) to show CV benefit in CKD associated with T2D. 1 Patients were included in this study if they had urine albumin-to-creatinine ratio (UACR) levels 30–5000 mg/g. 1 KERENDIA ® was approved in the United States on July 9, 2021 to reduce the risk of sustained eGFR decline, end-stage kidney disease, CV death, nonfatal myocardial infarction and hospitalization for heart failure in adult patients with CKD associated with T2D. 4

The KERENDIA ® label contains a Warning and Precaution that KERENDIA ® can cause hyperkalemia. 4 For more information, see “Important Safety Information” below.

“The unfortunate reality is that patients living with chronic kidney disease associated with type 2 diabetes are three times more likely to die from a cardiovascular event than those with type 2 diabetes alone. 5 As chronic kidney disease progresses, the risk for cardiovascular events and heart failure hospitalization increases, so early diagnosis and treatment is critical,” 6 said Bertram Pitt, professor of medicine emeritus at the University of Michigan School of Medicine in Ann Arbor and co-principal investigator of the FIGARO-DKD clinical trial. “The FIGARO-DKD study adds to the body of evidence that supports the benefits of finerenone for patients with chronic kidney disease associated with type 2 diabetes.” 1,3,7

ADVERTISEMENT

FIGARO-DKD: Second Phase III Study for Finerenone to Meet Primary Endpoint

FIGARO-DKD ( FI nerenone in reducin G c A rdiovascular mo R tality and m O rbidity in D iabetic K idney D isease), a randomized, double-blind, placebo-controlled trial, randomly assigned 7,437 participants from 48 countries to finerenone 10 mg or 20 mg orally once daily or placebo when added to standard of care, including blood glucose-lowering therapies and a maximum tolerated labeled dose of ACEis or ARBs. 1 Patients had UACR ≥30–<300 mg/g and eGFR ≥25–≤90 mL/min/1.73m 2 or UACR ≥300–≤5000 mg/g and eGFR ≥60 mL/min/1.73m 2. 1

In this study, the incidence of the key secondary endpoint, a composite of time to kidney failure, a sustained decrease of eGFR ≥40% from baseline over a period of at least four weeks, or renal death was lower with finerenone than with placebo, affecting 350 (9.5%) and 395 (10.8%) patients, respectively. 1 However, the difference was not statistically significant (HR 0.87 [95% CI, 0.76-1.01; P =0.0689]) over a median duration of follow-up of 3.4 years. 1 In the FIDELIO-DKD study, finerenone reduced the incidence of the primary composite endpoint of a sustained decline in eGFR of ≥40%, kidney failure or renal death (HR 0.82 [95% CI, 0.73-0.93; P =0.001]). 4 The treatment effect reflected a reduction in a sustained decline in eGFR of ≥40% and progression to kidney failure. There were few renal deaths during the trial. 4

In FIGARO-DKD, safety and tolerability profile were generally consistent with that of previously reported FIDELIO-DKD results. Overall, hyperkalemia-related adverse events occurred more often in patients receiving finerenone compared with placebo (10.8% and 5.3%, respectively). 1 Hospitalization due to hyperkalemia for the finerenone group was 0.6% versus <0.1% in the placebo group, and there was no hyperkalemia-related death in either treatment group. 1 Treatment was discontinued due to hyperkalemia in 1.2% of patients treated with finerenone compared to 0.4% in the placebo group. 1

FIDELITY: Prespecified Meta-analysis

Also presented within the ESC Hot Line session were select data from FIDELITY ( FI nerenone in chronic ki D ney diseas E and type 2 diabetes: combined FIDE L IO-DKD and F I GARO-DKD T rial program anal Y sis), which is a prespecified meta-analysis of the FIDELIO-DKD and FIGARO-DKD studies. FIDELITY is a meta-analysis of the largest Phase III program to evaluate the occurrence of progression of kidney disease as well as fatal and nonfatal CV events in >13,000 adult patients with CKD associated with T2D. 2,7

In this prespecified exploratory meta-analysis, finerenone reduced the risk of the composite CV outcome of time to CV death, nonfatal myocardial infarction, nonfatal stroke or hospitalization for heart failure by 14% compared with placebo. 2 The composite CV outcome occurred in 825 (12.7%) patients receiving finerenone and 939 (14.4%) patients receiving placebo (HR 0.86 [95% CI, 0.78–0.95]), with a number needed to treat of 46 at 36 months. 2 The reduction in the CV composite outcome was primarily driven by hospitalization for heart failure. Cardiovascular death and nonfatal myocardial infarction were directionally consistent with the CV composite outcome. 2 The composite kidney outcome of time to first onset of kidney failure, sustained ≥57% decrease in eGFR from baseline over ≥4 weeks, or renal death occurred in 360 (5.5%) patients receiving finerenone and 465 (7.1%) receiving placebo (HR 0.77 [95% CI, 0.67–0.88]). 2

In FIDELIO-DKD, this exploratory composite kidney outcome of kidney failure, sustained decrease in eGFR by 57% or more from baseline, or renal death occurred in 252 (8.9%) patients and 326 (11.5%) patients in the finerenone and placebo groups, respectively (HR 0.76 [95% CI, 0.65–0.90]). 3 In FIGARO-DKD, this exploratory composite kidney outcome of kidney failure, sustained decrease in eGFR by 57% or more from baseline, or renal death occurred in 108 (2.9%) patients and 139 (3.8%) patients in the finerenone and placebo groups, respectively (HR 0.77 [95% CI, 0.60–0.99]). 1 KERENDIA ® is not indicated to reduce the risk of renal death. 4

“With the results of the FIGARO-DKD study and FIDELITY analysis, we are very pleased to build on our growing body of evidence for finerenone in patients with chronic kidney disease associated with type 2 diabetes,” said Amit Sharma, M.D., Vice President of Cardiovascular and Renal, Bayer U.S. Medical Affairs. “Together, these findings reinforce our commitment to improving the lives of these patients.”

About Finerenone Phase III Clinical Trials Program

Having randomized more than 13,000 patients with CKD associated with T2D around the world, the Phase III program with finerenone in CKD associated with T2D comprises two studies, evaluating the effect of finerenone versus placebo on top of standard of care on both renal and cardiovascular outcomes. 7

The FIDELIO-DKD ( FI nerenone in reducing ki D n E y fai L ure and d I sease pr O gression in D iabetic K idney D isease) study was a randomized, double-blind, placebo-controlled, multicenter study in adult patients with CKD associated with T2D, defined as either having an UACR of 30 to 300 mg/g, eGFR 25 to 60 mL/min/1.73 m 2 and diabetic retinopathy, or as having an UACR of ≥300 mg/g and an eGFR of 25 to 75 mL/min/1.73 m. 3,4 The trial excluded patients with known significant non-diabetic kidney disease and a clinical diagnosis of chronic heart failure with reduced ejection fraction and persistent symptoms (NYHA class II to IV). 4 All patients were to have a serum potassium ≤4.8 mEq/L at screening and be receiving standard of care background therapy, including a maximum tolerated labeled dose of an ACEi or ARB. 4 A total of 5,674 patients were randomized to receive finerenone (N=2833) or placebo (N=2841) and were followed for a median of 2.6 years. 4 The mean age of the study population was 66 years, and 70% of patients were male. 4 The trial population was 63% White, 25% Asian, and 5% Black. 4

Finerenone reduced the incidence of the primary composite endpoint of a sustained decline in eGFR of ≥40%, kidney failure, or renal death (HR 0.82 [95% CI, 0.73-0.93; P =0.001]). 4 The treatment effect reflected a reduction in a sustained decline in eGFR of ≥40% and progression to kidney failure. 4 There were few renal deaths during the trial. 4

Finerenone also reduced the incidence of the composite endpoint of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke or hospitalization for heart failure (HR 0.86 [95% CI, 0.75-0.99; P =0.034]). 4 The treatment effect reflected a reduction in cardiovascular death, nonfatal myocardial infarction and hospitalization for heart failure. 4 Adverse reactions that occurred more commonly on finerenone than on placebo, and in at least 1% of patients treated with finerenone, were hyperkalemia (18.3% vs. 9%), hypotension (4.8% vs. 3.4%) and hyponatremia (1.4% vs. 0.7%). 4

FIGARO-DKD ( FI nerenone in reducin G c A rdiovascular mo R tality and m O rbidity in D iabetic K idney D isease) investigated the efficacy and safety of finerenone versus placebo in addition to standard of care on the reduction of cardiovascular morbidity and mortality in approximately 7,400 patients with CKD associated with T2D across 48 countries including sites in Europe, Japan, China and the U.S. 7,8 Finerenone 10 mg or 20 mg, orally once daily, was added to standard of care, including blood glucose-lowering therapies and a maximum tolerated labeled dose of an ACEi or an ARB. 7,8

Bayer also recently announced the initiation of the FINEARTS-HF study, a multicenter, randomized, double-blind, placebo-controlled Phase III study that will investigate finerenone compared to placebo in more than 5,500 symptomatic heart failure patients (New York Heart Association class II-IV) with a left ventricular ejection fraction of ≥40%. 9 The primary objective of the study is to demonstrate superiority of finerenone over placebo in reducing the rate of the composite endpoint of cardiovascular death and total (first and recurrent) heart failure (HF) events (defined as hospitalizations for HF or urgent HF visits). 9

About KERENDIA

INDICATION:

  • KERENDIA is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) 4

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS:

  • Concomitant use with strong CYP3A4 inhibitors 4
  • Patients with adrenal insufficiency 4

WARNINGS AND PRECAUTIONS:

  • Hyperkalemia: KERENDIA can cause hyperkalemia. The risk for developing hyperkalemia increases with decreasing kidney function and is greater in patients with higher baseline potassium levels or other risk factors for hyperkalemia. Measure serum potassium and eGFR in all patients before initiation of treatment with KERENDIA and dose accordingly. Do not initiate KERENDIA if serum potassium is >5.0 mEq/L 4

    Measure serum potassium periodically during treatment with KERENDIA and adjust dose accordingly. More frequent monitoring may be necessary for patients at risk for hyperkalemia, including those on concomitant medications that impair potassium excretion or increase serum potassium 4

MOST COMMON ADVERSE REACTIONS:

  • Adverse reactions reported in ≥1% of patients on KERENDIA and more frequently than placebo: hyperkalemia (18.3% vs. 9%), hypotension (4.8% vs. 3.4%), and hyponatremia (1.4% vs. 0.7%) 4

DRUG INTERACTIONS:

  • Strong CYP3A4 Inhibitors: Concomitant use of KERENDIA with strong CYP3A4 inhibitors is contraindicated. Avoid concomitant intake of grapefruit or grapefruit juice 4
  • Moderate and Weak CYP3A4 Inhibitors: Monitor serum potassium during drug initiation or dosage adjustment of either KERENDIA or the moderate or weak CYP3A4 inhibitor and adjust KERENDIA dosage as appropriate 4
  • Strong and Moderate CYP3A4 Inducers: Avoid concomitant use of KERENDIA with strong or moderate CYP3A4 inducers 4

USE IN SPECIFIC POPULATIONS:

  • Lactation: Avoid breastfeeding during treatment with KERENDIA and for 1 day after treatment 4
  • Hepatic Impairment: Avoid use of KERENDIA in patients with severe hepatic impairment (Child Pugh C) and consider additional serum potassium monitoring with moderate hepatic impairment (Child Pugh B) 4

Please read the Prescribing Information for KERENDIA.

About Chronic Kidney Disease Associated with Type 2 Diabetes

Patients with CKD associated with T2D are three times more likely to die from a cardiovascular-related cause than those with T2D alone. 5 CKD is a serious and progressive condition that is generally underrecognized. 10 CKD is a frequent complication arising from T2D and is also an independent risk factor of cardiovascular disease. 11,12,13 Approximately 40% of all patients with T2D develop CKD. 11 Despite guideline-directed therapies, patients with CKD associated with T2D remain at high risk of CKD progression and cardiovascular events. 12,13,14,15 T2D is the leading cause of end-stage kidney disease, which requires dialysis or a kidney transplant to stay alive. 16,17,18

About Bayer’s Commitment in Cardiovascular and Kidney Diseases

Bayer is an innovation leader in the area of cardiovascular diseases, with a long-standing commitment to delivering science for a better life by advancing a portfolio of innovative treatments. The heart and the kidneys are closely linked in health and disease, and Bayer is working in a wide range of therapeutic areas on new treatment approaches for cardiovascular and kidney diseases with high unmet medical needs. The cardiology franchise at Bayer already includes a number of products and several other compounds in various stages of preclinical and clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cardiovascular diseases are treated.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to www.bayer.com.

Find more information at www.pharma.bayer.com
Our online press service is just a click away: www.bayer.us/en/newsroom
Follow us on Facebook: http://www.facebook.com/pharma.bayer
Follow us on Twitter: https://twitter.com/BayerUS

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

References

View source version on businesswire.com:https://www.businesswire.com/news/home/20210828005016/en/

CONTACT: Media Contact:

Patti Fernandez, Tel. +1 845.300.4091

E-Mail:patricia.fernandez.ext@bayer.com

KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY

INDUSTRY KEYWORD: HEALTH FDA OTHER HEALTH GENERAL HEALTH RESEARCH SCIENCE PHARMACEUTICAL

SOURCE: Bayer

Copyright Business Wire 2021.

PUB: 08/28/2021 12:30 PM/DISC: 08/28/2021 12:32 PM

http://www.businesswire.com/news/home/20210828005016/en